EMA Calls Out to Companies Developing Ebola Treatments
The European Medicines Agency (EMA) is reviewing available information on Ebola treatments currently under development to “facilitate evidence-based decision-making” by health authorities.
The European Medicines Agency (EMA) is reviewing available information on Ebola treatments currently under development to “facilitate evidence-based decision-making” by health authorities.
At the moment there are no approved medicines to protect from or treat Ebola. Some experimental treatments have reportedly shown encouraging results in the laboratory or in animals, but they have not yet been fully studied in humans.
Over 5,300 cases of Ebola have been reported and more than 2,600 people have died. The current outbreak represents the widest geographical spread of the disease ever reported.
EMA has established a group of European experts with specialized knowledge in vaccines, infectious diseases and clinical trial design to contribute to the global response against Ebola. EMA Executive Director Guido Rasi has asked the Committee for Medicinal Products for Human Use (CHMP) to perform a formal review of the available scientific information; companies are invited to send all available quality, preclinical and clinical data about their treatments under development for review.
The companies identified so far include:
- Biocryst, a US-based company developing BCX 4430
- Fab’entech, from France, developing Hyperimmune horse sera
- MAPP Biologicals, a US-based company developing ZMAPP
- Sarepta, a US company developing Sarepta AVI-7537
- Toyama Chemicals, Fujifilm Group, based in Japan and MediVector Inc, based in the US, who are jointly developing Favipiravir
- Tekmira, a Canadian company developing TKM-Ebola
Companies that are not included in the list above but are also developing Ebola treatments are encouraged to contact the EMA. The review will focus on medicines under development that are used to treat people infected with the virus. Vaccines to protect people against contracting the disease and blood therapies involving the blood of survivors of Ebola infection are excluded from this review.
This entry was posted in
Europe
,
Global
,
healthcare
,
Regulatory
and tagged
Ebola
,
EMA
,
European Medicines Association
. Bookmark the
permalink
. Trackbacks are closed, but you can
post a comment
.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Merck’s Oral TLR7/8 Inhibitor Reduces Disease Activity in Cutaneous, Systemic Lupus
May 21st 2025Results from the Phase II WILLOW trial show that enpatoran achieved a statistically significant dose-response and clinically meaningful reduction in disease activity in cutaneous and systemic lupus erythematosus with active rash.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
